Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 3/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | TPH1 | P17752 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL972279 | 1.00 | SLC7A5 (0.57) | SLC7A5ESR1SLC6A2ALDH1A1CHRM1 | |
| Hydrochloric Acid SCHEMBL10587530 | 0.98 | SLC7A5 (0.56) | SLC7A5ESR1SLC6A2ALDH1A1CHRM1 | |
| Hydrochloric Acid SCHEMBL16007504 | 0.98 | SLC7A5 (0.56) | SLC7A5ESR1SLC6A2ALDH1A1CHRM1 | |
| SCHEMBL6001388 | 0.91 | SLC7A5 (0.54) | SLC7A5ESR1SLC6A2TSHRTAAR1 | |
| SCHEMBL16084879 | 0.91 | SLC7A5 (0.54) | SLC7A5ESR1SLC6A2TSHRTAAR1 | |
| SCHEMBL2271874 | 0.91 | SLC7A5 (0.54) | SLC7A5ESR1SLC6A2TSHRTAAR1 | |
| SCHEMBL17738628 | 0.90 | SLC7A5 (0.65) | SLC7A5ESR1SLC6A2TAAR1ESR2 | |
| SCHEMBL16007584 | 0.89 | SLC7A5 (0.53) | SLC7A5ESR1SLC6A2ALDH1A1CHRM1 | |
| SCHEMBL605205 | 0.89 | SLC7A5 (0.53) | SLC7A5ESR1SLC6A2ALDH1A1CHRM1 | |
| Hydrochloric Acid SCHEMBL27566032 | 0.89 | SLC7A5 (0.53) | SLC7A5ESR1SLC6A2TSHRTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103288630-A | Synthesizing method of Salvianic acid A sodium | UNIV SHANGHAI JIAOTONG | 2013-09-11 | — | — | CN | claimed |
| CN-102093578-A | Preparation method of shape-controllable amino-acid ester (with side group benzene ring) substituted polyphosphazene microspheres | UNIV BEIJING CHEMICAL | 2011-06-15 | — | — | CN | claimed |
| EP-1603549-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | Yu, Ruey J., Dr. (US) | 2005-12-14 | — | — | EP | claimed |
| US-20040220264-A1 | Bioavailability and improved delivery of acidic pharmaceutical drugs | YU RUEY J | 2004-11-04 | — | — | US | claimed |
| WO-2004082628-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-30 | — | — | WO | claimed |
| CN-120040435-A | Mangiferin and derivatives thereof, preparation method and medical application thereof | 安徽中医药大学 | 2025-05-27 | — | — | CN | disclosed |
| US-20200283479-A1 | Treatments for Gastrointestinal Disorders | IRONWOOD PHARMACEUTICALS INC (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200222541-A1 | LINACLOTIDE COMPOSITIONS | FOREST LABORATORIES HOLDINGS LTD (BM) | 2020-07-16 | — | — | US | disclosed |
| US-20190345190-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-17 | — | — | US | disclosed |
| EP-3539546-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| CN-106822101-B | A kind of epiphysin nano-composition and its preparation method and application | 刘卫 | 2019-08-23 | — | — | CN | disclosed |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040121316-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES, INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004035577-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035576-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003090691-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003091264-A2 | NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-6150491-A | PEROXIDATION OF AROMATIC COMPOUNDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2000-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222541-A1 | LINACLOTIDE COMPOSITIONS | LPXN, LPAR3, LPAR5 | SLC7A5 4314/4885ESR1 4729/4885SLC6A2 2037/4885 |
| US-20040121316-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | SLC7A5 3230/4885ESR1 1531/4885SLC6A2 4585/4885 |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | SLC7A5 1738/4885ESR1 201/4885SLC6A2 2156/4885 |
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | SLC7A5 1173/4885ESR1 3308/4885SLC6A2 2815/4885 |
| US-20200283479-A1 | Treatments for Gastrointestinal Disorders | GRPR, GIPR, GCGR | SLC7A5 3754/4885ESR1 4721/4885SLC6A2 4041/4885 |
| US-20190345190-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | SLC7A5 1173/4885ESR1 3308/4885SLC6A2 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.